Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 6:33 PM ET

Biotechnology

Company Overview of Intarcia Therapeutics, Inc.

Company Overview

Intarcia Therapeutics, Inc., a biopharmaceutical company, develops treatments to optimize therapeutic benefits and reduce adverse effects for chronic and life-threatening diseases. The company offers ITCA 650 for the treatment of type 2 diabetes by using its subcutaneous delivery system (its technology platform), which is a matchstick-sized device, including a cylindrical titanium alloy reservoir that is inserted under the skin to allow the water from the extracellular fluid to enter the device at one end by diffusing through a semi-permeable membrane directly into a salt osmotic engine that expands to drive a piston at a controlled rate of travel, and forces the drug formulation to be relea...

155 Seaport Boulevard

11th Floor

Boston, MA 02210

United States

Founded in 1995

35 Employees

Phone:

617-936-2500

Key Executives for Intarcia Therapeutics, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 47
Chief Financial Officer and Vice President of Finance & Operations
Age: 51
Chief Operating Officer
Chief Legal Officer, Vice President and General Counsel
Age: 56
Chief Business Officer and Head of Corporate Development
Age: 40
Compensation as of Fiscal Year 2015.

Intarcia Therapeutics, Inc. Key Developments

Intarcia Therapeutics, Inc. Announces Presentation of Results from its First Two Phase 3 Clinical Trials

Intarcia Therapeutics, Inc. announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association. Results showing positive data on key endpoints from the trials were highlighted in an oral presentation and a poster session at the conference in Boston. Oral Presentation of FREEDOM-1 Results Oral Presentation of FREEDOM-1: 'Clinical Impact of ITCA 650 in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled 39 Week Trial,'. FREEDOM-1, a placebo-controlled study, demonstrated positive results for ITCA 650 when added to diet and exercise with or without standard oral diabetes medications, for those patients who were not at goal. All key endpoints were met, including significant reductions in HbA1c and weight, and the percentage of patients treated to goal. ITCA 650 produced significant and sustained mean reductions in HbA1c of 1.4% at 39 weeks of treatment (mITT population). Two pre-specified patient populations were assessed to determine how HbA1c reductions may vary based on whether or not patients were on a background regimen including a sulfonylurea (SU)-based regimen, or a metformin or diet & exercise regimen without any SUs. Non SU-containing Regimens: Patients primarily on background metformin (40% of patients), or diet and exercise (11% of patients), showed a mean HbA1c reduction of 1.7%. SU-containing Regimens: Those on an SU-based background regimen (47% of patients) had a mean HbA1c reduction of 1.2%. Significant and progressive weight loss that was dose dependent was observed over 39 weeks (mITT population). Patients on the primary phase 3 dosing regimen lost a mean of 4 kg in the 60 mcg/d ITCA 650 dose group vs. 2 kg in the placebo group at Week 39, which was statistically significant. The overall tolerability profiles, including G.I. events, were very similar between the 40 mcg/d and the higher 60 mcg/d dose groups. There was a low single-digit discontinuation rate for nausea. No new safety findings were identified compared to what is known for the GLP-1 receptor agonist class. Other adverse events associated with the administration site and the procedures to place and remove the ITCA 650 were generally mild and transient. Discontinuations due to procedures and administration site adverse events were also a very low single digit rate across each arm of the 39-week study.

Intarcia Therapeutics, Inc. Names Emad Rizk to Board of Directors

Intarcia Therapeutics, Inc. announced the appointment of Emad Rizk, MD, to its board of directors. Dr. Rizk is a well-respected leader in the healthcare industry, and an expert on payers and healthcare economics. He joins the company board as the company nears completion of its clinical development for ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide), its lead therapeutic candidate for the treatment of type 2 diabetes. Dr. Rizk currently serves as President and Chief Executive Officer of Accretive Health. He previously served as President of McKesson Health Solutions. Dr. Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health.

Intarcia Therapeutics, Inc. Appoints Michael Williams as Chief Operating Officer

Intarcia Therapeutics, Inc. announced the appointment of Michael Williams into the newly created role of Chief Operating Officer (COO). Mr. Williams is a senior pharmaceutical executive with experience most recently at Takeda Pharmaceuticals, but also long and distinguished service at Pfizer and Bristol Myers Squibb. Mr. Williams will report directly to Kurt Graves, Intarcia's Chairman, President and CEO, and will be a member of the Leadership Team. He will have full accountability, in cooperation with the Executive Team, for building out the commercial capabilities and operational plans for ITCA 650, Intarcia's late-stage development candidate for the treatment of type 2 diabetes. Prior to joining Intarcia, Mr. Williams was Head of Global Marketing for Takeda Pharmaceuticals where he was responsible for establishing Takeda's first Global Marketing organization that included Global Market Access, Customer Insights and Global Brand Management.

Similar Private Companies By Industry

Company Name Region
Regulon Inc. United States
PharmatrophiX, Inc. United States
Arvinas, Inc. United States
JGL, Inc. United States
Integene International Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 27, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intarcia Therapeutics, Inc., please visit www.intarcia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.